PE
Insider
Pamela Esposito
DirectorPamela Esposito (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Kymera Therapeutics, Inc. (KYMR). The largest single filing was $2.2M of KYMR (26,563 sh across 3 lots, as filed), executed Dec 17 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.7M
shares × price, as filed
Last traded
Feb 20
Filed Feb 20
Median ADV $102.3M across their filed names
Open performance→Volume by month
Buys $0
Sells $3.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
KYMRRecent filings
KYMRSALE
Kymera Therapeutics, Inc.
View filing →
$165K1,900 sh × $87.06
Exec Feb 20
Filed Feb 20 · 5:30 PM ET KYMRSALE Kymera Therapeutics, Inc. View filing → $333K
4,900 sh × $67.99
Exec Jan 20
Filed Jan 20 · 5:30 PM ET KYMRSALE Kymera Therapeutics, Inc. View filing → $2.2M
26,563 sh across 3 lots
Exec Dec 17 2025
Filed Dec 17 2025 · 5:30 PM ET KYMRSALE Kymera Therapeutics, Inc. View filing → $245K
5,000 sh × $49.04
Exec Jun 3 2025
Filed Jun 3 2025 · 5:30 PM ET KYMRSALE Kymera Therapeutics, Inc. View filing → $122K
2,500 sh × $49.00
Exec Dec 2 2024
Filed Dec 2 2024 · 5:30 PM ET KYMRSALE Kymera Therapeutics, Inc. View filing → $652K
13,500 sh across 2 lots
Exec Sep 17 2024
Filed Sep 17 2024 · 5:30 PM ET